Dear Editor,

The pandemic of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) highlights the need to develop effective and safe vaccines. Similar to SARS-CoV, SARS-CoV-2 recognizes angiotensin-converting enzyme 2 (ACE2) as receptor for host cell entry.^[@CR1],[@CR2]^ SARS-CoV-2 spike (S) protein consists of S1, including receptor-binding domain (RBD), and S2 subunits.^[@CR3],[@CR4]^ We previously demonstrated that RBDs of SARS-CoV and MERS-CoV serve as important targets for the development of effective vaccines.^[@CR5],[@CR6]^

To identify an mRNA candidate vaccine, we initially designed two mRNA constructs expressing S1 and RBD, respectively, of SARS-CoV-2 S protein (Fig. [1a](#Fig1){ref-type="fig"}). Both culture supernatants and lysates of cells transfected with S1 or RBD mRNA reacted strongly with a SARS-CoV-2 RBD-specific antibody (Supplementary information, Fig. [S1a](#MOESM1){ref-type="media"}), demonstrating expression of the target proteins.Fig. 1Design and evaluation of SARS-CoV-2 S1 and RBD mRNA vaccines.**a** Schematic diagram of SARS-CoV-2 S1 and RBD mRNA construction. The synthesized nucleoside-modified S1 and RBD mRNAs were encapsulated with LNPs to form mRNA-LNPs. **b**--**j** IgG and neutralizing antibodies induced in immunized BALB/c mice at different immunogen doses via intradermal (I.D.) prime and boost at 4 weeks. Sera at 10 days post-2nd immunization with SARS-CoV-2 S1 or RBD mRNA-LNP (e.g., S1-LNP or RBD-LNP) (30 μg/mouse), or empty LNP (control), were detected for SARS-CoV-2 RBD-specific IgG antibodies by ELISA (**b**) or neutralizing antibodies against pseudotyped (**c**) and live (**d**) SARS-CoV-2 infection. Sera at 10, 40, and 70 days post-2nd immunization with above mRNA-LNPs (10 μg/mouse) or control were detected for neutralizing antibodies against pseudotyped (**e**--**g**) and live (**h**--**j**) SARS-CoV-2 infection. The ELISA plates were coated with SARS-CoV-2 RBD-Fc protein (1 µg/ml), and IgG antibody (Ab) titer was calculated. Overall, 50% neutralizing antibody titer (nAb NT~50~) was calculated against SARS-CoV-2 pseudovirus infection in hACE2/293T cells, or against live SARS-CoV-2 infection by a cytopathic effect (CPE)-based microneutralization assay in Vero E6 cells. The dotted lines indicate detection limit. **k** Dose-dependent inhibition of sera of mice receiving a vaccine (30 μg/mouse) on SARS-CoV-2 RBD-hACE2 receptor binding in hACE2/293T cells by flow cytometry analysis. Percent (%) inhibition was calculated based on relative fluorescence intensity with or without respective serum at indicated dilutions. **l**--**n** Representative images of such inhibition by sera (1:5) of mice immunized with SARS-CoV-2 S1 mRNA-LNP (S1-LNP) (**l**), RBD mRNA-LNP (RBD-LNP) (**m**), or empty LNP control (**n**) are shown in blue lines with respective median fluorescence intensity (MFI) values. The binding between SARS-CoV-2 RBD-Fc protein (5 µg/mL) and hACE2 is shown in red lines. Gray shades indicate Fc-hACE2 binding. **o** Cross-reactivity of immunized mouse sera against SARS-CoV RBD by ELISA. SARS-CoV RBD-Fc protein-coated plates (1 µg/mL) were used to detect IgG Ab titer. **p**--**r** Cross nAb NT~50~ of above sera (twofold serial dilutions from 1:5) against infection of SARS-CoV pseudovirus expressing S protein of human SARS-CoV strains Tor2 (**p**) and GD03 (**q**), or palm civet SARS-CoV strain SZ3 (**r**) in hACE2/293T cells. Data (**b**, **c**, **e**--**g**, **k**--**r**) are presented as means ± SEM of mice (*n* = 5); data (**d**, **h**--**j**) are presented as means ± SEM of duplicate wells of pooled sera from five mice per group. Significant differences are shown as \**P* \< 0.05; \*\**P* \< 0.01; \*\*\**P* \< 0.001. Experiments were repeated twice with similar results.

To detect whether S1 and RBD mRNAs durably express antigens in multiple cell types, we constructed N-terminal mCherry-tagged SARS-CoV-2 S1 and RBD mRNAs, encapsulated them with lipid nanoparticles (LNPs) (Supplementary information, Fig. [S1b](#MOESM1){ref-type="media"}), and tested mCherry expression. Relative to the control, both RBD- and S1-mCherry mRNAs showed robust protein expression in cells for at least 160 h, with higher expression of the RBD construct (Supplementary information, Fig. [S2a](#MOESM1){ref-type="media"}). In addition, these mRNAs expressed proteins efficiently in a variety of human (A549, Hep-2, HEP-G2, Caco-2, HeLa, 293 T), monkey (Vero E6), and bat (Tb1-Lu) cell lines (Supplementary information, Fig. [S2b](#MOESM1){ref-type="media"}). Particularly, the expression of RBD-mCherry protein was higher than that of S1-mCherry protein in all cell lines tested (Supplementary information, Fig. [S2b](#MOESM1){ref-type="media"}). These data indicate long-term and broad expression of mRNA-encoding proteins, particularly RBD, in target cells.

We then characterized LNP-encapsulated S1 and RBD mRNAs for stability and subcellular localization. The mCherry-tagged S1 and RBD showed strong and stronger fluorescence intensity, respectively, irrespective of incubation temperature (4 or 25 °C) and culture time (0, 24, or 72 h) (Supplementary information, Fig. [S3a](#MOESM1){ref-type="media"}). S1- and RBD-mCherry proteins were not colocalized with nuclei but associated with lysosomes (Supplementary information, Fig. [S3b](#MOESM1){ref-type="media"}). These results suggest that LNP-encapsulated SARS-CoV-2 S1 and RBD mRNAs are stable at various temperatures and may be resistant to lysosomal degradation.

We next evaluated T follicular helper (Tfh), germinal center (GC) B, and plasma cell responses induced by SARS-CoV-2 S1 and RBD mRNA-LNPs in BALB/c mice. Mice were intradermally (I.D.) prime and boost immunized with each mRNA-LNP (30 μg/mouse) or empty LNP control, and draining lymph nodes or spleens were tested for Tfh, GC B, or plasma cells 10 days post-2nd immunization (Supplementary information, Fig. [S4a](#MOESM1){ref-type="media"}). The percentages of Tfh cells (Supplementary information, Fig. [S5a](#MOESM1){ref-type="media"}) and GC B cells (Supplementary information, Fig. [S5b](#MOESM1){ref-type="media"}) were higher or significantly higher in the lymph nodes of RBD mRNA-LNP-immunized mice than in those of S1 mRNA-LNP-immunized mice, whereas only a background level of Tfh and GC B cells was shown in the LNP control-injected mice. Plasma cells were also significantly increased in splenocytes of the vaccinated mice, as compared to the control group (Supplementary information, Fig. [S5c](#MOESM1){ref-type="media"}). These data demonstrate the recruitment of Tfh, GC B, and/or plasma cells *in vivo*, particularly after immunization with SARS-CoV-2 RBD mRNA-LNP vaccine.

We further evaluated humoral immune responses and neutralizing antibodies induced by S1 and RBD mRNA-LNPs. Mice were immunized with each mRNA-LNP at three different schedules (Supplementary information, Fig. [S4a--c](#MOESM1){ref-type="media"}), and sera were collected for detection of IgG, subtype (IgG1 and IgG2a), and neutralizing antibodies. First, ELISA results revealed that S1 and RBD mRNA-LNPs (30 μg/mouse, I.D. prime and boost) induced RBD-specific IgG (Fig. [1b](#Fig1){ref-type="fig"}), IgG1 (Th2) (Supplementary information, Fig. [S5d](#MOESM1){ref-type="media"}), and IgG2a (Th1) (Supplementary information, Fig. [S5e](#MOESM1){ref-type="media"}) antibodies 10 days after boost immunization and that IgG antibody titer induced by RBD was significantly higher than that by S1 (Fig. [1b](#Fig1){ref-type="fig"}). Pseudovirus neutralization assay showed that S1 and RBD mRNA-LNPs elicited neutralizing antibodies against SARS-CoV-2 pseudovirus entry into human ACE2-expressing 293T (hACE2/293T) cells; particularly, RBD elicited significantly higher-titer neutralizing antibodies than S1 (Fig. [1c](#Fig1){ref-type="fig"}). Neutralizing antibodies, particularly those induced by RBD mRNA-LNP, also potently neutralized live SARS-CoV-2 infection (Fig. [1d](#Fig1){ref-type="fig"}). Next, both S1 and RBD mRNA-LNPs (10 μg, I.D. prime and boost) induced SARS-CoV-2 RBD-specific IgG (Supplementary information, Fig. [S6a](#MOESM1){ref-type="media"}) and neutralizing antibodies against SARS-CoV-2 pseudovirus infection (Fig. [1e](#Fig1){ref-type="fig"}) 10 days after boost dose, and maintained at similarly high levels for 40 and 70 days post-boost immunization, while the titer of neutralizing antibodies elicited by RBD mRNA-LNP was always significantly higher than that by S1 mRNA-LNP (Fig. [1f, g](#Fig1){ref-type="fig"}; Supplementary information, [S6b, c](#MOESM1){ref-type="media"}). Importantly, RBD mRNA-LNP induced antibody levels that potently neutralized live SARS-CoV-2 infection, reaching peak titer at 70 days post-2nd immunization and being significantly more potent than SARS-CoV-2 S1 mRNA-LNP-induced antibodies (Fig. [1h--j](#Fig1){ref-type="fig"}). Finally, RBD mRNA-LNP (10 μg, I.D. prime and intramuscular (I.M.) boost) also elicited significantly higher-titer RBD-specific IgG (Supplementary information, Fig. [S6d](#MOESM1){ref-type="media"}) or neutralizing antibodies than S1 mRNA-LNP against SARS-CoV-2 pseudovirus (Supplementary information, Fig. [S6g](#MOESM1){ref-type="media"}) and live SARS-CoV-2 (Supplementary information, Fig. [S6j](#MOESM1){ref-type="media"}) infection 10 days after boost immunization, and such antibodies maintained at similar or even higher levels for at least 70 days post-boost dose (Supplementary information, Fig. [S6e, f, h, i, k, l](#MOESM1){ref-type="media"}). In contrast, empty LNP control only elicited a background, or undetectable, level of antibodies incapable of neutralizing SARS-CoV-2 infection (Fig. [1b--j](#Fig1){ref-type="fig"}; Supplementary information, Fig. [S6](#MOESM1){ref-type="media"}). These data suggest that RBD mRNA-LNP vaccine immunized at different immunogen doses and variant routes induced strong RBD-specific antibody responses and potent neutralizing antibodies against pseudotyped and live SARS-CoV-2 infection.

To substantiate antiviral activity, we found the binding of SARS-CoV-2 RBD to ACE2 receptor in hACE2/293T cells was inhibited by serum antibodies produced from RBD or S1 mRNA-LNP-vaccinated mice. Specifically, anti-RBD antibodies potently inhibited, in a dose-dependent manner, RBD-ACE2 receptor binding, which was much stronger than anti-S1 antibodies (Fig. [1k--m](#Fig1){ref-type="fig"}), while the control LNP-induced mouse sera did not inhibit RBD-ACE2 binding (Fig. [1k, n](#Fig1){ref-type="fig"}). These data suggest that RBD mRNA-LNP-induced antibodies can potently block binding between SARS-CoV-2 RBD and its ACE2 receptor.

Since SARS-CoV-2 RBD shares about 70% sequence identity with SARS-CoV RBD,^[@CR7]^ we evaluated whether serum antibodies from SARS-CoV-2 mRNA-LNPs may cross-react with SARS-CoV RBD and neutralize SARS-CoV infection. ELISA results showed that the titer of IgG (Fig. [1o](#Fig1){ref-type="fig"}), IgG1 (Supplementary information, Fig. [S5f](#MOESM1){ref-type="media"}), and IgG2a (Supplementary information, Fig. [S5g](#MOESM1){ref-type="media"}) antibodies induced by SARS-CoV-2 RBD mRNA-LNP was higher, or significantly higher, than those by SARS-CoV-2 S1 mRNA-LNP in cross-reacting with SARS-CoV RBD and cross-neutralizing infection by three SARS-CoV pseudoviruses expressing S proteins of human strains Tor2 (Fig. [1p](#Fig1){ref-type="fig"}), GD03 (Fig. [1q](#Fig1){ref-type="fig"}), and palm civet strain SZ3 (Fig. [1r](#Fig1){ref-type="fig"}), respectively. These results suggest that SARS-CoV-2 RBD mRNA vaccine can elicit antibodies cross-reacting with SARS-CoV RBD and cross-neutralizing SARS-CoV infection.

We also investigated SARS-CoV-2 RBD-specific T cell responses induced by S1 and RBD mRNA-LNPs in immunized mice. Splenocytes collected 10 days post-2nd immunization were stimulated with SARS-CoV-2 RBD overlapping peptides (Supplementary information, Table [S1](#MOESM1){ref-type="media"}), and detected for secretion of IFN-γ (Th1), TNF-α (Th1), and IL-4 (Th2) in CD45^+^CD4^+^ T cells, as well as IFN-γ, TNF-α, and IL-4 in CD45^+^CD8^+^ T cells by flow cytometry analysis. Compared with the LNP control, immunization with RBD mRNA-LNP could significantly increase the frequency of IFN-γ-, TNF-α- or IL-4-producing CD45^+^CD4^+^ (Supplementary information, Fig. [S7a--c](#MOESM1){ref-type="media"}) or CD45^+^CD8^+^ (Supplementary information, Fig. [S7d--f](#MOESM1){ref-type="media"}) T cells, respectively. However, S1 mRNA-LNP could only significantly increase the frequency of TNF-α-producing CD45^+^CD4^+^ (Supplementary information, Fig. [S7b](#MOESM1){ref-type="media"}) and IFN-γ- or IL-4-producing CD45^+^-CD8^+^ (Supplementary information, Fig. [S7d, f](#MOESM1){ref-type="media"}) T cells, respectively. Therefore, RBD mRNA vaccine can effectively elicit RBD-specific CD45^+^CD4^+^ (Th1) and CD45^+^CD8^+^ T cell responses.

As opposed to DNA, mRNA does not enter the nucleus and is not lysed by lysosomal enzymes (Supplementary information, Fig. [S8](#MOESM1){ref-type="media"}),^[@CR8]^ contributing to its high stability and translation efficiency. GC, where GC B cells interact with Tfh and B cells, is the major site for production of high-affinity antibodies.^[@CR9]^ Here, we showed that RBD mRNA-LNP elicited strong Tfh and GC B cell responses and potent neutralizing antibodies able to inhibit the binding between SARS-CoV-2 RBD and ACE2 receptor (Supplementary information, Fig. [S8](#MOESM1){ref-type="media"}), demonstrating its high potency against SARS-CoV-2 infection.

The repertoire of COVID-19 vaccines currently in clinical trials include mRNA, adenovirus, and DNA-based vaccines, most of which encode SARS-CoV-2 full-length S protein.^[@CR10]--[@CR12]^ It has been shown that adenovirus-based ChAdOx1 nCoV-19 vaccine elicits specific IgG antibody titer of 1:400--6400 and neutralizing antibody titer of 1:5--40, whereas the DNA vaccine induces a neutralizing antibody titer of 1:74--170, against live virus infection in immunized monkeys.^[@CR10],[@CR11]^ In addition, neutralizing antibody titer against pseudotyped SARS-CoV-2 infection ranged from 1:89--1115 in mice immunized with a full-length S-based mRNA vaccine.^[@CR12]^ Here we found that a SARS-CoV-2 RBD-based mRNA vaccine at 30 μg/mouse elicited SARS-CoV-2 RBD-specific IgG antibody titer (\~1:230,000) and neutralizing antibody titer in mice against pseudotyped and live SARS-CoV-2 infection at \~1:10,000 and 1:540, respectively. Moreover, immunization with this vaccine at a lower immunogen dose (10 μg) via variant immunization routes (I.D. prime and I.D. or I.M. boost) also induced high-titer IgG antibodies with neutralizing activity against pseudotyped and live SARS-CoV-2 infection that persisted for at least 70 days during the detection period. Thus the IgG and neutralizing antibody titers induced by the RBD-based mRNA vaccine were higher than those reported, suggesting beneficial protection against SARS-CoV-2 challenge in vivo. Future studies warrant evaluation of protective efficacy using mRNA vaccine against other reported vaccines under development. Previous studies showed that SARS-CoV full-length S protein induced harmful immune responses with enhanced infection or liver damage after virus challenge, raising safety concerns.^[@CR6]^ In contrast, RBD-based SARS-CoV and MERS-CoV vaccines had no evidence to cause harmful immune responses, including eosinophilic immune enhancement.^[@CR5],[@CR6]^ Although no obvious adverse effects have been reported in currently developed COVID-19 vaccines, cautions need to be paid regarding their safety. More studies will be needed to investigate vaccine-associated immunopathology in addition to evaluate their protective efficacy.

Overall, this study identifies RBD as a key antigen to design effective vaccines against SARS-CoV-2, indicating great potential of RBD-based mRNA vaccine for mitigation of the COVID-19 pandemic and possible SARS-related epidemics in the future. The strategy of developing RBD-based mRNA COVID-19 vaccine, as described herein, can also be applied to develop vaccines against other emerging and reemerging coronavirus diseases in the future.
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